Built on Expand Health, the clinics where the study runs: Expand Health, Cape Town Expand Labs, Bucharest
GLP-1 retention

The engine that keeps people on GLP-1 treatment.

We tell the prescriber which patients are about to drop off, before they sign the next refill.

A ranked queue of patients, each with weeks on treatment, a weight trend and a refill signal

See the engine work.

A look at the weekly check on the patient's phone, and what reaches the prescriber at the refill.

The problem

More than half of patients stop a GLP-1 within the first year, before they have had the benefit.

53.6% discontinue within 12 months. JAMA Network Open, 2025.

What it does before each refill.

1

It sits on top of the clinic's own system and writes nothing back.

2

It reads the orders the clinic already holds, and a weekly check from the patient's phone.

3

At the refill it surfaces the patient with the evidence, and drafts the message a clinician would send.

4

The clinician decides. Nothing about the dose is automated.

A diagram showing the clinic's system underneath, with the engine reading the weekly check and the orders on top
The engine runs on top of the system the clinic already has.
A ranked list of patients with weeks on treatment, a weight trend line and a refill signal for each
Patients about to drop off come first in the queue.
The single patient row that needs a decision, with the weight history attached and a drafted message
The row that needs a decision, with the evidence and a drafted message.

Screens are illustrative, with synthetic patients.

A held-back control group measures the retention it adds.
Who it is for

A provider that bills monthly loses the subscription as soon as a patient stops. Payers and employers have paid for a drug the patient is no longer taking, and pharma loses sight of the patient once the drug is dispensed.

Design partners

Shaped by the clinics closest to the problem.

We develop this with clinics and prescribers, around the way they already handle a refill.

Expand Health, Cape Town Expand Labs, Bucharest Nordic Laboratories

Who is building it.

Emilian Popa
Co-founder and CEO
Matthias Wojcik
Co-founder and Chief Science Officer

We want to hear from anyone who prescribes GLP-1 treatment, pays for it, or makes it.